Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis Through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells

(Cell Reports 25, 1018–1026.e1–e4; October 23, 2018) In the originally published version of this article, the word “Cells” in the title was mistakenly changed to “Sells” during the production process. The title has been corrected online and also appears here. The production team apologizes for the error. Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma CellsBadur et al.Cell ReportsOctober 23, 2018In BriefBadur et al. apply metabolic flux analysis to understand how oncogenic mutations in IDH1 alter redox metabolism. Production of (D)2-hydroxyglutarate (D2HG) consumes NADPH at levels similar to de novo lipogenesis, and removal of lipids compromises in vitro growth of IDH1-mutant cells. Full-Text PDF Open Access